COVID-19 and Psoriatic Disease

IFPA’s global advice

The COVID-19 pandemic has shocked the world and disrupted the lives of people living with psoriatic disease. In the face of this pandemic, it is IFPA’s mission to deliver the most credible and reliable information regarding COVID-19 and psoriatic disease.

IFPA is proud to partner with PsoProtect and PsoProtectMe.

PsoProtect is an international registry for healthcare providers to report outcomes of COVID-19 in individuals with psoriasis. The registry's sister survey, PsoProtectMe, is collecting self-reported data from people living with psoriatic disease through the COVID-19 pandemic.

The results of these projects have increased our understanding of how the COVID-19 pandemic is affecting people with psoriatic disease. New insights will continue to inform clinical recommendations and better response to future emergencies.

Help us understand the impact of COVID-19

You can participate in PsoProtectMe, whether or not you have experienced symptoms of COVID-19.

The information on this page is not intended as a substitute for professional medical advice, diagnosis, or treatment. Please note that IFPA does not guarantee the accuracy, relevance, timeliness, or completeness of any information from external sources. Always refer to the World Health Organization and local healthcare authorities for the most up-to-date information about COVID-19.